Multidisciplinary Consideration of Frontline Modalities Should Guide Decisions in Melanoma With In-Transit Metastases
Source: Onc Live, October 2023
Danielle K. DePalo, MD, explains the lack of research directly comparing first-line treatment options for patients with unresectable melanoma in-transit metastases, expands on the safety and efficacy of 3 treatment modalities for these patients, and underscores the need for more data to inform the management of these patients.
Selecting between isolated limb infusion/perfusion (ILI/P), immune checkpoint inhibition (ICI), and intratumoral therapy (IT) in the first-line setting for patients with surgically unresectable melanoma in-transit metastases necessitates multidisciplinary collaboration and consideration of the risks and benefits of each modality, according to Danielle K. DePalo, MD.
Findings from a retrospective chart review of these 3 modalities were presented at the 2023 ASCO Annual Meeting and showed that ICI therapy (n = 121) was associated with greater short-term toxicity necessitating pharmacological intervention vs IT (n = 86) and ILI/P (n = 353), at 44.1% vs 18.0% and 20.4%, respectively. ICI therapy was also associated with increased toxicities requiring hospitalization (22.1%) vs IT (1.4%) and ILI/P (9.2%).